Tarsus Pharmaceuticals, Inc.
TARSDrugs in Pipeline
7
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
7wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
TP-03, 0.25%
Blepharitis
TP-03 Vehicle
Blepharitis
TP-03
Meibomian Gland Dysfunction
TP-05 (lotilaner) Low Dose
Lyme Disease
Lotilaner Gel, 2.0%
Papulopustular Rosacea
Vehicle of TP-03
Meibomian Gland Dysfunction
Low Dose TP-05
Healthy Volunteer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TP-03, 0.25% | Phase 3 | Blepharitis | - | - |
TP-03 Vehicle | Phase 3 | Blepharitis | - | - |
TP-03 | Phase 3 | Meibomian Gland Dysfunction | - | - |
TP-05 (lotilaner) Low Dose | Phase 2 | Lyme Disease | - | - |
Lotilaner Gel, 2.0% | Phase 2 | Papulopustular Rosacea | - | - |
Vehicle of TP-03 | Phase 2 | Meibomian Gland Dysfunction | - | - |
Low Dose TP-05 | Phase 2 | Healthy Volunteer | - | - |
Blepharitis
2 drugs in this indication
Meibomian Gland Dysfunction
2 drugs in this indication
Healthy Volunteer
1 drug in this indication
Papulopustular Rosacea
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)